Bristol-Myers,Pfizer Report Results Of Post-hoc Subanalysis From ARISTOTLE Trial

(RTTNews) - Bristol-Myers Squibb Co. (BMY) and Pfizer Inc. (PFE) announced results of a post-hoc subanalysis from the Phase III ARISTOTLE trial. The companies noted that this subanalysis was presented at the ESC Congress 2013, organized by the European Society of Cardiology, in Amsterdam, The Netherlands.

The results showed that in the 30-day period following a procedure, rates of clinical events (stroke or systemic embolism, major bleeding, and all-cause death) were comparable in the Eliquis and warfarin treatment arms.

Among patients treated with Eliquis, event rates in the 30-day period following a procedure were similar whether Eliquis was stopped prior to the procedure or continued during the procedure. In patients taking warfarin, there was at least a twofold higher rate of major bleeding and death during the 30-day period following a procedure when warfarin was continued during the procedure compared to when warfarin was stopped prior to the procedure.